The Activation of PDGFRβ on Mononuclear Stromal/Tumor Cells in Giant Cell Tumor of Bone After Denosumab Treatment. An Immunohistochemical Study of Five Cases

Due to the relatively high recurrence rate and the destructive nature of the tumor, the treatment of giant cell tumor is still a challenge. Denosumab appeared to be a promising candidate as a therapeutic drug. However, several studies have reported that tumors can recur during/after treatment with denosumab. Based on activated receptor tyrosine kinase signaling pattern of the stromal/tumor cells, a combination treatment with denosumab and sunitinib has recently been proposed to inhibit recurrences. This prompted us to investigate the PDGFRβ expression of five denosumab treated cases using both primary and recurrent tumors during and after denosumab treatment. In addition, to recognise morphological changes, immunohistochemical analysis of H3F3A and PDGFRβ was also performed. As an effect of denosumab treatment, the permanent absence of giant cells associated with severe to mild fibrosis was the most consistent morphological change, but H3F3A positive stromal/tumor cells were observed in all cases. Furthermore, an increased immunopositivity of PDGFRβ in stromal/tumor cells was evident in all recurrent cases during denosumab treatment. Upon tumor recurrence (after the discontinuation of denosumab treatment) the intensity of PDGFRβ immunostaining in stromal/tumor cells was restored/decreased. Our results confirm (for the first time) the activation of PDGFRβ on mononuclear stromal/tumor cells at protein level as an effect of denosumab treatment, which has so far only been demonstrated by phosphoprotein array analysis (protein lysates). The decreased PDGFRβ activity after the discontinuation of denosumab treatmeant and the increased PDGFRβ activity during denosumab treatment underlines the need for denosumab and sunitinib combination therapy.

[1]  P. Hogendoorn,et al.  Cell Biology of Giant Cell Tumour of Bone: Crosstalk between m/wt Nucleosome H3.3, Telomeres and Osteoclastogenesis , 2021, Cancers.

[2]  J. Neradil,et al.  New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRβ Signaling , 2021, Cancers.

[3]  L. Aponte-Tinao,et al.  Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation , 2021, Scientific Reports.

[4]  J. Blay,et al.  Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab , 2021, BMC Cancer.

[5]  Xi Chen,et al.  Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis , 2020, BMC Musculoskeletal Disorders.

[6]  H. Gelderblom,et al.  Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone , 2019, Current opinion in oncology.

[7]  K. Ghaffarzadehgan,et al.  Denosumab in Patients with Giant Cell Tumor and Its Recurrence: A Systematic Review. , 2018, The archives of bone and joint surgery.

[8]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[9]  A. Flanagan,et al.  H3F3A (Histone 3.3) G34W Immunohistochemistry , 2017, The American journal of surgical pathology.

[10]  G. Farfalli,et al.  Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls. , 2017, Human pathology.

[11]  J. Blay,et al.  Giant cell tumour of bone in the denosumab era. , 2017, European journal of cancer.

[12]  A. Flanagan,et al.  H 3 F 3 A ( Histone 3 . 3 ) G 34 W Immunohistochemistry A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone , 2017 .

[13]  A. Flanagan,et al.  Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone , 2017 .

[14]  R. Mohankumar,et al.  Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone. , 2016, European journal of cancer.

[15]  G. Matcuk,et al.  Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy , 2015, Skeletal Radiology.

[16]  M. Stratton,et al.  Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone , 2013, Nature Genetics.

[17]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[18]  David M. Thomas,et al.  Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. , 2010, The Lancet. Oncology.

[19]  P. Hogendoorn,et al.  Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array‐CGH analysis , 2009, Genes, chromosomes & cancer.

[20]  M. Szendrői,et al.  Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. , 2008, The Journal of bone and joint surgery. American volume.

[21]  M. Balke,et al.  Giant cell tumor of bone: treatment and outcome of 214 cases , 2008, Journal of Cancer Research and Clinical Oncology.

[22]  A. Evdokiou,et al.  RANK Expression as a Cell Surface Marker of Human Osteoclast Precursors in Peripheral Blood, Bone Marrow, and Giant Cell Tumors of Bone , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  H. Yoshida,et al.  Giant cell tumor of bone , 2004, Virchows Archiv A.

[24]  M. Szendröi Giant-cell tumour of bone. , 2004, The Journal of bone and joint surgery. British volume.

[25]  E. Milgrom,et al.  RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. , 2002, American journal of clinical pathology.